Verici Dx (Verici Dx) Receivables Turnover

: 1.00 (As of Jun. 2023)

View and export this data going back to 2021. Start your Free Trial

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Verici Dx's Revenue for the six months ended in Jun. 2023 was $0.02 Mil. Verici Dx's average Accounts Receivable for the six months ended in Jun. 2023 was $0.02 Mil. Hence, Verici Dx's Receivables Turnover for the six months ended in Jun. 2023 was 1.00.

Verici Dx Receivables Turnover Historical Data

The historical data trend for Verici Dx's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verici Dx Annual Data

Trend

Dec20

Dec21

Dec22

Receivables Turnover

Verici Dx Semi-Annual Data
	Jun21	Dec21	Jun22	Dec22	Jun23
Receivables Turnover	-	-	-	-	1.00

Competitive Comparison

For the Diagnostics & Research subindustry, Verici Dx's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Verici Dx Receivables Turnover Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Verici Dx's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where Verici Dx's Receivables Turnover falls into.

Verici Dx Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

Verici Dx's Receivables Turnover for the fiscal year that ended in Dec. 2022 is calculated as

	Receivables Turnover (A: Dec. 2022 )
=	Revenue	/	Average Total Inventories
=	Revenue (A: Dec. 2022 )	/ (	(Accounts Receivable (A: Dec. 2021 )	+	Accounts Receivable (A: Dec. 2022 ))	/	count )
=	0	/ (	(0	+	0)	/	1 )
=	0	/	0
=	N/A

Verici Dx's Receivables Turnover for the quarter that ended in Jun. 2023 is calculated as

	Receivables Turnover (Q: Jun. 2023 )
=	Revenue	/	Average Total Inventories
=	Revenue (Q: Jun. 2023 )	/ (	(Accounts Receivable (Q: Dec. 2022 )	+	Accounts Receivable (Q: Jun. 2023 ))	/	count )
=	0.019	/ (	(0	+	0.019)	/	1 )
=	0.019	/	0.019
=	1.00

Verici Dx (OTCPK:VRCDF) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.

Verici Dx Receivables Turnover Related Terms

Thank you for viewing the detailed overview of Verici Dx's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.

Verici Dx (Verici Dx) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Verici Dx PLC (OTCPK:VRCDF) » Definitions » Receivables Turnover

Comparable Companies

Traded in Other Exchanges

VRCI:UK

Address

19 Stanwell Road, Avon House, Penarth, Cardiff, GBR, CF64 2EZ

Website

https://www.vericidx.com

Verici Dx PLC is an immuno-diagnostics development company. The company is focused on developing diagnostics technologies which will help understand the outcomes of an organ transplant surgery. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; and Tuteva, a post-transplant diagnostic focused upon acute cellular rejection including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels. The business of the Group comprises a single activity, that of the development of prognostic and diagnostic tests for kidney transplant patients.

Verici Dx (Verici Dx) Headlines

No Headlines